Citations

Clear

16281 citation(s) found for "Yu, David".

Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Shirani, Mahsa , Levin, Solomon , Shebl, Bassem , Requena, David , Finkelstein, Tova M. , Johnson, Daniel S. , Ng, Denise , Heissel, Søren , Højrup, Peter , Molina, Henrik , Rice, Charles M. , Lyons, Barbara A. , Simon, Sanford M. , Lalazar, Gadi , Heissel, Søren , Hojrup, Peter , Molina, Henrik , de Jong, Ype P , Rice, Charles M , Singhi, Aatur Dilip , Torbenson, Michael S , Coffino, Philip , Lyons, Barbara , Simon, Sanford M , Requena, David , Levin, Solomon N , Jong, Ype P. de , Torbenson, Michael

Mayo Clinic

Cancer Research | June 18, 2024 | Volume: 84 | Issue: 16 | Pages: 2626-2644

10.1158/0008-5472.can-23-4110 | PMID 38888469 Get It

Abstract Fibrolamellar hepatocellular carcinoma (FLC) is a rare liver cancer that is driven by the fusion of DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). PKA activity is controlled through regulatory proteins that both inhibit catalytic activity and control localization, and an excess of regulatory subunits ensures PRKACA activity is inhibited. Here, we found an increase in the ratio of catalytic to regulatory units in FLC patient tumors driven by DNAJB1::PRKACA using mass spectrometry, biochemistry, and immunofluorescence, with increased nuclear localization of the kinase. Overexpression of DNAJB1::PRKACA, ATP1B1::PRKACA, or PRKACA, but not catalytically inactive kinase, caused similar transcriptomic changes in primary human hepatocytes, recapitulating the changes observed in FLC. Consistently, tumors in patients missing a regulatory subunit or harboring an ATP1B1::PRKACA fusion were indistinguishable from FLC based on the histopathological, transcriptomic, and drug–response profiles. Together, these findings indicate that the DNAJB1 domain of DNAJB1::PRKACA is not required for FLC. Instead, changes in PKA activity and localization determine the FLC phenotype. Significance: Alterations leading to unconstrained protein kinase A signaling, regardless of the presence or absence of PRKACA fusions, drive the phenotypes of fibrolamellar hepatocellular carcinoma, reshaping understanding of the pathogenesis of this rare liver cancer.
NFS-21. DEMOGRAPHIC, CLINICAL AND IMAGING CHARACTERISTICS OF NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1: RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
Fisher, Michael J. , Listernick, Robert , Liu, Grant, Ferner, Rosalie E. , Lasky-Zeid, Janice, Ullrich, Nicole J. , Stasheff, Steven F., Rosser, T.H.L., Borcher, March, Arden-Holmes, Simone, Flaherty, Maree , Hummel, Trent R. , Motley, Walker, Bielamowicz, Kevin , Phillips, Paul H. , Reginald, Arun, Peragallo, Jason H. , Sato, Aimee , Hogan, Nick, McCourt, Emily A. , Ranka, Milan P., Campen, Cynthia , Beres, Shannon , Stearns, Duncan , Örge, Faruk , O’Halloran, Henry S., Oattes, Julius, Reddy, Alyssa , Brodsky, Michael A., Donahue, Sean P., Blank, Peter M K de , Gutmann, David H. , Heidary, Gena , Bornhorst, Miriam , Rosser, Teena, Bouffet, Éric , Wolf, David S. , El-Dairi, Mays , Mater, David Van , Tarczy‐Hornoch, Kristina , Klesse, Laura J. , Foreman, Nicholas K. , Allen, Jeffrey C. , Moertel, Christopher L. , Areaux, Raymond G. , Crawford, John Ross , Brodsky, Michael, Esbenshade, Adam J. , Cutter, Gary , Avery, Robert A.

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.579 Get It

Abstract BACKGROUND Treatment and clinical management decisions for children with NF1-OPGs remain challenging as most existing data are retrospective and have not included standardized visual outcomes. In this study, we prospectively enrolled newly diagnosed NF1-OPGs and performed standardized neuro-oncology and ophthalmology assessments in order to develop evidence-based guidelines for monitoring and treatment. METHODS Children with NF1-OPG on MRI who were evaluated by both a study ophthalmologist and neuro-oncologist/NF1 expert within 1 month of radiologic diagnosis were eligible for enrollment. All subjects attempted quantitative visual acuity using Teller acuity cards (TAC) as well as ATS-HOTV testing. The neuro-oncologist/NF1 expert provided reasons for obtaining the MRI as well as initiating treatment, if applicable. Descriptive statistics calculated the success rate of acquiring TAC and reasons to obtain the MRI. RESULTS Two-hundred fifty subjects from 22 institutions were enrolled and had at least one visit beyond baseline (Median age 3.1 years, range 0.1–16.8; 53% female). TAC was successfully acquired in both eyes (N=195, 78%) and at least one eye in (N=206, 82%). ATS-HOTV was successfully acquired in both eyes (N=97, 39%) and at least one eye in (N=98, 39%). The two most common reasons to obtain an MRI were screening due to a diagnosis of NF1 (N=99, 39%) and ophthalmologic concern (N=81, 32%). At enrollment, continued observation occurred in a majority of subjects (N=221, 88%) while treatment with chemotherapy was initiated in only 11% (N=29). Twenty-nine (11%) subjects initially observed transitioned to treatment after enrollment (range: 2.5–25 months) thus far. DISCUSSION We present a prospective multicenter study of children with newly diagnosed NF1-OPGs. The ability to acquire quantitative visual acuity was higher than anticipated. The frequency of NF1-OPGs requiring treatment is lower than previously reported. Regression models of clinical and MRI features that prompted immediate treatment with chemotherapy versus observation will be discussed.
NFS-24. TUMOR VOLUME IN NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1 (NF1-OPG): PRELIMINARY RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
Jiang, Zhifan , Parida, Abhijeet , Listernick, Robert , Liu, Grant, Ferner, Rosalie E. , Lasky-Zeid, Janice, Ullrich, Nicole J. , Stasheff, Steven F., Rosser, T.H.L., Arden-Holmes, Simone, Flaherty, Maree , Hummel, Trent R. , Motley, Walker, Bielamowicz, Kevin , Phillips, Paul H. , Reginald, Arun, Peragallo, Jason H. , El-Diari, Mays, Sato, Aimee , Hogan, Nick, McCourt, Emily A. , Ranka, Milan P., Campen, Cynthia , Beres, Shannon , Stearns, Duncan , Örge, Faruk , O’Halloran, Henry S., Brodsky, Michael A., Donahue, Sean P., Oattes, Julius, Reddy, Alyssa , Linguraru, Marius George , Fisher, Michael J. , Avery, Robert A. , Gutmann, David H. , Blank, Peter M K de , Heidary, Gena , Bornhorst, Miriam , Rosser, Teena, Borchert, Mark , Bouffet, Éric , Wolf, David S. , Mater, David Van , Tarczy‐Hornoch, Kristina , Klesse, Laura J. , Foreman, Nicholas K. , Allen, Jeffrey C. , Moertel, Christopher L. , Areaux, Raymond G. , Crawford, John Ross , Brodsky, Michael, Esbenshade, Adam J. , Cutter, Gary

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.582 Get It

Abstract BACKGROUND NF1-OPGs are amorphous tumors involving either single or multiple locations (optic nerve, chiasm, tract) along the anterior visual pathway (AVP). In this prospective study, we investigated how volumetric MRI measures of the AVP as well as other clinical variables are associated with treatment decisions in children with newly diagnosed NF1-OPGs. METHODS Children with newly diagnosed NF1-OPG whose MRI included a T1-weighted volumetric sequence without significant artifact at their enrollment visit were eligible for inclusion. All subjects underwent a quantitative ophthalmic exam to determine if visual acuity (VA) was normal. The neuro-oncologist/NF1 expert determined whether the subject would be observed or undergo treatment at that baseline visit. Volumetric MRI analysis was automatically performed using a deep learning network that measured AVP volume (mm3). Non-parametric group comparisons and multivariable logistic regression models evaluated the impact of age at enrollment, sex, NF1 inheritance type, AVP volume, and VA on the decision for immediate treatment with chemotherapy versus observation. RESULTS One-hundred twenty-three subjects met inclusion criteria. Subjects assigned to observation (N=112, 44% female) and subjects immediately treated with chemotherapy (N=11, 80% female) at enrollment were of similar age (2.7 and 2.8 years, respectively) and inheritance (p > 0.05). Abnormal VA was present more often in the treatment group (46%) compared to the observation group (17%, p <0.001). AVP volume was significantly greater in the treatment group (4,181.1mm3) compared to the observation group (1,819.8mm3, p <0.001). AVP volume, sex, and VA reached significance in univariable regression, however, in the multivariable regression model only the AVP volume (p < 0.001) was significantly associated with treatment initiation. DISCUSSION Children with greater NF1-OPG AVP volumes are treated more often compared with those with lower volumes. Volumetric measures of NF1-OPGs are a valuable metric in understanding treatment patterns and are positioned to help inform clinical decision making.
Correlation Between Calcium Scoring and Abdominal Aortic Aneurysm Endovascular Repair Outcomes
Farres, Houssam , Lanka, Santh Prakash , Nussbaum, Sam, Shoukry, Mira , Hanouneh, Tareq, Sella, David M., Alexander, Lauren, Sella, David, Alexander, Lauren F. , Jarmi, Tambi

Mayo Clinic

Vascular and Endovascular Surgery | June 17, 2024 | Volume: 58 | Issue: 7 | Pages: 723-732

10.1177/15385744241263696 | PMID 38886243 Get It

Objectives Endovascular aneurysm repair, though minimally invasive and has the benefit of relatively low perioperative complication rates, it is associated with significant long term reintervention rates related to endoleaks. Several variables have been studied to predict the outcomes of endovascular aneurysm repair, 1 of which is the calcium burden of the vasculature. This prompted us to study the association between calcium burden measured by the standardized Agatston scoring system and the outcomes of Endovascular aneurysm repair. Methods This is a retrospective study of patients who underwent Endovascular aneurysm repair from 2008 to 2020 at our institution and who had a non-contrast computerized tomography scan preoperatively, accounting for 87 patients. The calcium burden of the vasculature was measured by the Agatston scoring system allowing for better reproducibility, and the outcome variables included mortality and endoleaks. Results Patients with higher median total calcium scores (≥12966.9) had significantly lesser survival (79.8% vs 52.3% ( P = .002) at five years compared to patients with lower median total calcium score (<12966.9). Also, patients with type 2 endoleaks had higher calcium scores in above the aneurysm level ((1591.2 vs 688.2), P = .05)) compared to patients with no type 2 endoleaks. Conclusion Calcium score assigned using a standardized Agatston scoring system can be used as a predictor of mortality risk assisting in deciding the treatment of choice for patients.
Epidemiologic Features of Recovery From SARS-CoV-2 Infection
Oelsner, Elizabeth C. , Sun, Yifei , Andrews, Howard , Carson, April P. , Cushman, Mary , Demmer, Ryan T. , Elkind, Mitchell S.V. , Gallo, Linda C. , Kandula, Namratha R. , Kaplan, Robert C. , Kucharska-Newton, Anna M., Lee, Joyce , Norwood, Arnita F. , Ortega, Victor E. , Gabriel, Kelley Pettee , Sotres‐Alvarez, Daniela , Shikany, James M., Thyagarajan, Bharat , Umans, Jason G. , Wenzel, Sally E. , Woodruff, Prescott G. , Zhang, Ying , Kucharska‐Newton, Anna , Carson, April P , Thyagarajan, Bharat , Oelsner, Elizabeth C , Kucharska-Newton, Anna M , Demmer, Ryan T , Lee, Joyce S , Wenzel, Sally E , Balte, Pallavi , Allen, Norrina B. , Cole, Shelley A. , Coresh, Josef , Couper, David , Daviglus, Martha , Gutierrez, Jose D., Howard, Virginia J. , Isasi, Carmen R. , Judd, Suzanne E. , Kanaya, Alka M , Kinney, Gregory L. , Lackland, Daniel T. , Make, Barry J. , Min, Yuan‐I , Murabito, Joanne M. , Psaty, Bruce M. , Regan, Elizabeth Anne , Schwartz, David A. , Tracy, Russell P. , Vasan, Ramachandran S. , Xanthakis, Vanessa , Post, Wendy S. , Wenzel, Sally E.

Mayo Clinic

JAMA Network Open | June 17, 2024 | Volume: 7 | Issue: 6 | Pages: e2417440

10.1001/jamanetworkopen.2024.17440 | PMID 38884994 Get It

ImportancePersistent symptoms and disability following SARS-CoV-2 infection, known as post–COVID-19 condition or “long COVID,” are frequently reported and pose a substantial personal and societal burden.ObjectiveTo determine time to recovery following SARS-CoV-2 infection and identify factors associated with recovery by 90 days.Design, Setting, and ParticipantsFor this prospective cohort study, standardized ascertainment of SARS-CoV-2 infection was conducted starting in April 1, 2020, across 14 ongoing National Institutes of Health–funded cohorts that have enrolled and followed participants since 1971. This report includes data collected through February 28, 2023, on adults aged 18 years or older with self-reported SARS-CoV-2 infection.ExposurePreinfection health conditions and lifestyle factors assessed before and during the pandemic via prepandemic examinations and pandemic-era questionnaires.Main Outcomes and MeasuresProbability of nonrecovery by 90 days and restricted mean recovery times were estimated using Kaplan-Meier curves, and Cox proportional hazards regression was performed to assess multivariable-adjusted associations with recovery by 90 days.ResultsOf 4708 participants with self-reported SARS-CoV-2 infection (mean [SD] age, 61.3 [13.8] years; 2952 women [62.7%]), an estimated 22.5% (95% CI, 21.2%-23.7%) did not recover by 90 days post infection. Median (IQR) time to recovery was 20 (8-75) days. By 90 days post infection, there were significant differences in restricted mean recovery time according to sociodemographic, clinical, and lifestyle characteristics, particularly by acute infection severity (outpatient vs critical hospitalization, 32.9 days [95% CI, 31.9-33.9 days] vs 57.6 days [95% CI, 51.9-63.3 days]; log-rank P &amp;lt; .001). Recovery by 90 days post infection was associated with vaccination prior to infection (hazard ratio [HR], 1.30; 95% CI, 1.11-1.51) and infection during the sixth (Omicron variant) vs first wave (HR, 1.25; 95% CI, 1.06-1.49). These associations were mediated by reduced severity of acute infection (33.4% and 17.6%, respectively). Recovery was unfavorably associated with female sex (HR, 0.85; 95% CI, 0.79-0.92) and prepandemic clinical cardiovascular disease (HR, 0.84; 95% CI, 0.71-0.99). No significant multivariable-adjusted associations were observed for age, educational attainment, smoking history, obesity, diabetes, chronic kidney disease, asthma, chronic obstructive pulmonary disease, or elevated depressive symptoms. Results were similar for reinfections.Conclusions and RelevanceIn this cohort study, more than 1 in 5 adults did not recover within 3 months of SARS-CoV-2 infection. Recovery within 3 months was less likely in women and those with preexisting cardiovascular disease and more likely in those with COVID-19 vaccination or infection during the Omicron variant wave.
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.
Yoon, Harry H. , Raymond, Eric, Hubner, Richard , Shu, Yongqian , Pan, Yueyin , Zhang, Jingdong , Park, Sook Ryun , Kojima, Takashi , Lin, Chen‐Yuan , Li, Liyun , Wu, Hongqian, Peng, Yanyan , Yan, Shican, Kato, Ken , Raymond, Éric , Jiang, Yi , Wyrwicz, Lucjan , Tougeron, David , Ishihara, Ryu , Xu, Jianming

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 4032-4032

10.1200/jco.2024.42.16_suppl.4032 Get It

4032 Background: RATIONALE-306 (NCT03783442) is the first global study to investigate anti-programmed cell death protein 1 therapy in combination with different chemotherapy (chemo) options in the first-line (1L) treatment of advanced/metastatic esophageal squamous cell carcinoma (ESCC). At interim analysis (IA), tislelizumab (TIS) plus chemo demonstrated a statistically significant, clinically meaningful improvement in overall survival (OS) versus placebo (PBO) plus chemo, with a manageable safety profile. Here, we report updated efficacy and safety data with minimum 3 years’ follow-up after study unblinding at IA. Methods: Adults with unresectable locally advanced recurrent/metastatic ESCC and no prior systemic treatment for advanced disease were enrolled and randomized (1:1; stratified by region, prior definitive therapy, and investigator [INV]-chosen chemo) to receive TIS 200 mg (Arm A) or PBO (Arm B) IV every 3 weeks plus chemo (platinum plus fluoropyrimidine or platinum plus paclitaxel), until disease progression or intolerable toxicity. The primary endpoint was OS in the intent-to-treat population. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR), all per INV, and safety. Results: In total, 649 patients (pts) were randomized (Arm A, n=326; Arm B, n=323). At a minimum study follow-up of 36.0 months, improvements in OS, PFS, and DoR in Arm A versus B (Table) were maintained relative to the IA. The hazard ratio (HR) for OS with TIS plus chemo versus PBO plus chemo was 0.70 (95% confidence interval: 0.59, 0.83). Similar to the IA, incidences of any-grade (96.6% vs 96.3%) or grade ≥3 (67.0% vs 64.5%) treatment-related adverse events (TRAEs) were comparable between Arms A and B, respectively; treatment-emergent adverse events leading to treatment discontinuation were higher in Arm A (32.1%) versus B (22.1%). In Arm A versus B, respectively, serious TRAEs occurred in 29.9% vs 19.6% of pts; TRAEs leading to death occurred in 1.9% and 1.2%. Conclusions: After minimum 3 years’ follow-up, 1L TIS plus chemo continued to demonstrate clinically meaningful improvements in OS and PFS and durable antitumor response benefit versus PBO plus chemo in pts with advanced/metastatic ESCC, with no new safety signals. Clinical trial information: NCT03783442 . [Table: see text]
Phase II study of neoadjuvant short-course radiotherapy combined with CAPEOX plus envafolimab in patients with microsatellite stable locally advanced rectal cancer: Updated results of PRECAM study.
Zhang, Feixiang , Shi, Liming , Wang, Yunfei , Shen, Yanbin , Xu, Lingna , Hu, Peng , Tang, Wen, Xu, Dengyong, Shan, Lina , Jia, Xiya, Chen, Yiyi , Wang, Da , Lao, Weifeng , Sun, Xiaonan , Dai, Sheng , Wang, Fei , Lv, Yiming , Hu, Peng, Larson, David W. , Gu, Hongcang , Huang, Xuefeng

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3614-3614

10.1200/jco.2024.42.16_suppl.3614 Get It

3614 Background: Conventional neoadjuvant chemoradiotherapy (nCRT) yields a pathologic complete response (pCR) rate of about 15%–- 30% for locally advanced rectal cancer (LARC). This PRECAM study aimed to investigate the efficacy and safety of neoadjuvant short-course radiotherapy combined with CAPEOX plus Envafolimab in Patients with Microsatellite Stable (MSS) LARC, redefining the standard of care (SOC) for LARC. Methods: The study is an open-label, prospective, single-arm, phase II clinical study . Eligible patients with MSS LARC were consecutively enrolled. Participants received short-course radiotherapy (25Gy/5f) with subsequent two cycles of CAPEOX (capecitabine and oxaliplatin) and 6 cycles of Envafolimab (subcutaneous injection, 150 mg, QW ) followed by total mesorectal excision surgery. The primary endpoint was pathological complete response (pCR) rate, and the secondary endpoint was major pathologic (MPR) rate and safety. Results: From April to December 2022, 34 patients were enrolled, of whom 32 completed the study. Remarkably, The pCR rate was62.5% (20/32), and the (MPR) rate was 75% (24/32). Furthermore, 65.6% (21/32) patients achieved a neoadjuvant rectal (NAR) score below 8, suggesting an effective treatment response. Common adverse events included tenesmus (78.1%), diarrhea (62.5%), and leukocyte decrease (40.6%), with two cases of Grade 3 adverse events. Surgical procedures were performed in all 32 cases, with minor complications observed. During the follow-up period of up to 20 months, no recurrence or death were reported. Conclusions: Short-course radiotherapy combined with CAPEOX plus Envafolimab showed favorable pCR rate with manageable adverse effects and surgical complications in LARC, underscoring the potential of the combination therapy for MSS LARC. A Randomized controlled trial is warranted for further exploration and validation. Clinical trial information: NCT05216653 .
The goals for successful development of treatment in gastroparesis
Yang, David Yi , Camilleri, Michael

Mayo Clinic

Neurogastroenterology & Motility | June 17, 2024 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/nmo.14849 | PMID 38884392 Get It

AbstractBackgroundGastroparesis is a motility disorder of the stomach characterized by cardinal symptoms and delayed gastric emptying of solid food in the absence of mechanical obstruction. There is significant unmet need in its management, and essentially there are no medications approved for its treatment over four decades.PurposeThe objectives of this review are to develop an understanding of the goals of treatment, the evidence‐based criteria for treatment success based on the current scientific understanding of gastroparesis as well as patient response outcomes, and to propose evidence‐based principles for the successful development of treatments for gastroparesis. Specifically, we discuss the pathophysiologic targets in gastroparesis, eligibility criteria for clinical trial participation based on validated gastric emptying studies, and the patient response outcome measures that have been validated to appraise effects of treatment on clinically relevant outcomes. These considerations lead to recommendations regarding eligibility, design, and duration of proof‐of‐efficacy studies, and to endorsing the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary as a validated patient response outcome and to justification of the shortening of proof‐of‐efficacy, placebo‐controlled clinical trials to 4 weeks treatment duration after a baseline period. We believe that such approaches will increase the likelihood of successful assessment of efficacy of novel approaches to treating patients with gastroparesis.
University of Washington Quality of Life subdomain outcomes after treatment of sinonasal malignancy: A prospective, multicenter study
Maoz, Sabrina L. , Golzar, Autreen , Hwang, Peter H. , Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chan, Erik, Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Lazor, Jillian W. , Nabavizadeh, Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Sim, Myung‐Shin , Choby, Garret , Hwang, Peter H , Wang, Eric W , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Kingdom, Todd T , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Beswick, Daniel , Maoz, Sabrina L , Choby, Garret , Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Pinheiro‐Neto, Carlos , Fischer, Jakob L. , Abuzeid, Waleed M. , Nayak, Jayakar V. , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D. , Beswick, Daniel M.

Mayo Clinic

International Forum of Allergy & Rhinology | June 17, 2024 | Volume: 14 | Issue: 10 | Pages: 1568-1581

10.1002/alr.23386 | PMID 38884276 Get It

AbstractPurposeSinonasal malignancies (SNMs) adversely impact patients’ quality of life (QOL) and are frequently identified at an advanced stage. Because these tumors are rare, there are few studies that examine the specific QOL areas that are impacted. This knowledge would help improve the care of these patients.MethodsIn this prospective, multi‐institutional study, 273 patients with SNMs who underwent definitive treatment with curative intent were evaluated. We used the University of Washington Quality of Life (UWQOL) instrument over 5 years from diagnosis to identify demographic, treatment, and disease‐related factors that influence each of the 12 UWQOL subdomains from baseline to 5 ‐years post‐treatment.ResultsMultivariate models found endoscopic resection predicted improved pain (vs. nonsurgical treatment CI 2.4, 19.4, p = 0.01) and appearance versus open (CI 27.0, 35.0, p < 0.001) or combined (CI 10.4, 17.1, p < 0.001). Pterygopalatine fossa involvement predicted worse swallow (CI −10.8, −2.4, p = 0.01) and pain (CI −17.0, −4.0, p < 0.001). Neck dissection predicted worse swallow (CI −14.8, −2.8, p < 0.001), taste (CI −31.7, −1.5, p = 0.02), and salivary symptoms (CI −28.4, −8.6, p < 0.001). Maxillary involvement predicted worse chewing (CI 9.8, 33.2; p < 0.001) and speech (CI −21.8, −5.4, p < 0.001) relative to other sites. Advanced T stage predicted worse anxiety (CI −13.0, −2.0, p = 0.03).ConclusionsSurgical approach, management of cervical disease, tumor extent, and site of involvement impacted variable UWQOL symptom areas. Endoscopic resection predicted better pain, appearance, and chewing compared with open. These results may aid in counseling patients regarding potential QOL expectations in their SNM treatment and recovery course.
Patterns of cognitive domain abnormalities enhance discrimination of dementia risk prediction: The ARIC study
Pike, James Russell , Sharrett, A. Richey, Windham, B. Gwen , Sullivan, Kevin , Albert, Marilyn , Yaşar, Sevil , Burgard, Sheila , Gross, Alden L. , Sullivan, Kevin J , Pike, James R , Knopman, David S. , Gottesman, Rebecca F. , Mosley, Thomas H. , Walker, Keenan A. , Li, David D.-U.

Mayo Clinic

Alzheimer's & Dementia | June 15, 2024 | Volume: 20 | Issue: 7 | Pages: 4559-4571

10.1002/alz.13876 | PMID 38877664 Get It

AbstractINTRODUCTIONThe contribution of neuropsychological assessments to risk assessment for incident dementia is underappreciated.METHODSWe analyzed neuropsychological testing results in dementia‐free participants in the Atherosclerosis Risk in Communities (ARIC) study. We examined associations of index domain–specific neuropsychological test performance with incident dementia using cumulative incidence curves and Cox proportional hazards models.RESULTSAmong 5296 initially dementia‐free participants (mean [standard deviation] age of 75.8 [5.1] years; 60.1% women, 22.2% Black) over a median follow‐up of 7.9 years, the covariate‐adjusted hazard ratio varied substantially depending on the pattern of domain‐specific performance and age, in an orderly manner from single domain language abnormalities (lowest risk) to single domain executive or memory abnormalities, to multidomain abnormalities including memory (highest risk).DISCUSSIONBy identifying normatively defined cognitive abnormalities by domains based on neuropsychological test performance, there is a conceptually orderly and age‐sensitive spectrum of risk for incident dementia that provides valuable information about the likelihood of progression.Highlights Domain‐specific cognitive profiles carry enhanced prognostic value compared to mild cognitive impairment. Single‐domain non‐amnestic cognitive abnormalities have the most favorable prognosis. Multidomain amnestic abnormalities have the greatest risk for incident dementia. Patterns of domain‐specific risks are similar by sex and race.